))
Dr. Jeremy Levin, Chairman and CEO of Ovid Therapeutics a
Manage episode 302029583 series 2893097
Contenu fourni par Dean Fanelli and Dr. Dean Fanelli. Tout le contenu du podcast, y compris les épisodes, les graphiques et les descriptions de podcast, est téléchargé et fourni directement par Dean Fanelli and Dr. Dean Fanelli ou son partenaire de plateforme de podcast. Si vous pensez que quelqu'un utilise votre œuvre protégée sans votre autorisation, vous pouvez suivre le processus décrit ici https://fr.player.fm/legal.
Dr. Jeremy Levin, Chairman and CEO of Ovid Therapeutics and the immediate past Chairman of the global Biotechnology Innovation Organization (BIO), shares his latest thoughts on today's COVID-19 news:
A new study in The Lancet Infectious Diseases shows Delta variant doubles the risk of hospitalization for the unvaccinated compared to the Alpha strain. New infections are up 21 percent in the last 14 days. Nationwide, COVID deaths are up 355 percent since early July. The increasing use (and benefit) of monoclonal antibody treatments. CNBC just reported on HHS data indicating that the use of mABS has increased significantly. The Lilly, Vir and Regeneron mABs are increasingly approved for use in a number of states. For those in the US, the mABs are an option for those over 65 or with pre-existing conditions who are diagnosed with Covid. An unvaccinated elementary school teacher in Marin, CA, infected half her class when she removed her mask to read aloud. "War call" in NYC streets as anti-vaxxers protest DeBlasio vaccine mandate for everyone 12 and over. Ivermectin spikes calls to Arkansas' poisons hotline after lawmakers encourage its use to treat COVID—in defiance of CDC recommendations. Ivermectin poison calls this year were four times higher than those of the past four years combined.
51 episodes
Partager
